OptiBiotix Health PLC Exercise of Warrants and Issue of Equity (9046T)

TIDMOPTI

RNS Number : 9046T

OptiBiotix Health PLC

11 January 2017

11 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Exercise of Warrants and Issue of Equity

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that the Company has received notification from a warrant holder to exercise a warrant as set out below:-

 
 Number of ordinary      Exercise   Proceeds to the 
  shares of 2p nominal    price      Company 
  value issued under 
  warrant 
----------------------  ---------  ---------------- 
 29,375                  8p         GBP2,350 
----------------------  ---------  ---------------- 
 

Application will be made to the London Stock Exchange to admit the 29,375 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 17 January 2017. The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 78,193,634 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

 
 OptiBiotix Health plc                                                    www.optibiotix.com 
 Stephen O'Hara, Chief                                                  Contact via Walbrook 
  Executive                                                                            below 
 
 Cairn Financial Advisers                                                 Tel: [phone] 
  LLP (NOMAD) 
 Liam Murray / Richard 
  Nash 
 
 finnCap (Broker)                                                         Tel: [phone] 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate 
  Broking) 
 
 Walbrook PR Ltd                             Tel: [phone] or [e-mail] 
 Anna Dunphy                                                              Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGMGMMGMGGNZM

(END) Dow Jones Newswires

January 11, 2017 05:04 ET (10:04 GMT)